Influenza virus vaccine - Vaccitech

Drug Profile

Influenza virus vaccine - Vaccitech

Alternative Names: MVA-NP+M1

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vaccitech
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 02 Nov 2017 Vaccitech Limited and University of Oxford completes a phase I trial in Healthy volunteers (NCT03277456)
  • 13 Oct 2017 Vaccitech initiates enrolment in the phase II INVICTUS trial for Influenza virus infections (Prevention) in United Kingdom (NCT03300362)
  • 01 Oct 2017 Vaccitech completes the phase II RIVET trial for Influenza virus infections in United Kingdom (ISRCTN60691705)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top